Decades of misguided trade policies have transformed the United States into the world’s consumer of last resort, absorbing the world’s excess savings at the expense of its manufacturing sector. U.S.-imposed tariffs are the first step towards rebalancing the system, but they aren’t sufficient.
The American pharmaceutical supply chain has become dangerously dependent on imports and foreign-controlled supply chains. Over the past 20 years, the country has experienced a skyrocketing rate on pharmaceutical imports and increasing foreign reliance.
Yes, reshoring manufacturing is possible. Investors will even go along for the ride, Guardian Bikes CEO Brian Riley told the Senate Small Business Committee in a hearing on May 14.
A smart policy like the ‘PILLS Act’ would prioritize domestic production of essential generics. It’s precisely the market signal needed to attract serious investment and rebuild the industry at home.
Under the so-called “Big Beautiful Bill” as passed by the House, Chinese solar companies will no longer qualify for renewable energy tax benefits under the Inflation Reduction Act (IRA) of 2022.
Some Chinese solar power inverters were allegedly found to have communication devices attached to them that were not supposed to be part of that equipment, suggesting that they can ping information back to the company’s headquarters and be used for nefarious ends, Reuters London reported on May 14.
The Trump Administration is leading a realignment on trade, moving away from a unipolar system that really had Asia as the Western world’s manufacturing hub. That is no longer feasible, or affordable.
CPA’s submission documents how the domestic trucking sector underpins U.S. commerce, and that ensuring a domestic industrial base for producing these trucks is vital to military readiness and civil emergency response.
As the leading organization advocating for reshoring the generic drug industry, CPA’s submission documents how extreme overreliance on foreign pharmaceutical supplies—especially active pharmaceutical ingredients (APIs) and critical injectable drugs from China and India—poses an urgent threat to U.S. national security and patient safety.
This month’s tariff agreements with the United Kingdom and China might end up being the first deal of its kind, and the last. On Friday, President Trump reiterated that the administration could not possibly strike deals with every country, and that tariff announcements would be made over the next two to three weeks.
